Recent advances in cancer immunotherapy—ranging from immune-checkpoint blockade
therapy to adoptive cellular therapy and vaccines—have revolutionized cancer treatment …

T cell engineering has changed the landscape of cancer immunotherapy. Chimeric antigen
receptor T cells have demonstrated a remarkable efficacy in the treatment of B cell …

The accurate identification of antitumor T cell receptors (TCRs) represents a major challenge
for the engineering of cell-based cancer immunotherapies. By mapping 55 neoantigen …

Interaction of the T cell receptor (TCR) with an MHC-antigenic peptide complex results in
changes at the molecular and cellular levels in T cells. The outside environmental cues are …

Cancer immunotherapies, including adoptive T cell transfer, can be ineffective because
tumors evolve to display antigen-loss-variant clones. Therapies that activate multiple …

Immunotherapies such as immune checkpoint blockade (ICB) and adoptive cell therapy
(ACT) have revolutionized cancer treatment, especially in patients whose disease was …

The remarkable capacity of immunotherapies to induce durable regression in some patients
with metastatic cancer relies heavily on T cell recognition of tumor-presented antigens. As …

Major histocompatibility class I (MHC I) molecules bind peptides derived from a cell's
expressed genes and then transport and display this antigenic information on the cell …

Immunotherapy is regarded as the most promising treatment for cancers. Various cancer
immunotherapies, including adoptive cellular immunotherapy, tumor vaccines, antibodies …

Infection susceptibility, poor vaccination efficacy, age-related disease onset, and neoplasms
are linked to innate and adaptive immune dysfunction that accompanies aging (known as …